©2024 Stanford Medicine
The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis
Not Recruiting
Trial ID: NCT02632786
Purpose
This is a global, multicenter, Phase 2b, randomized, double-blind, placebo-controlled,
two-arm, parallel-group efficacy and safety study of NEOD001 as a single agent administered
intravenously in adults with AL amyloidosis who had a hematologic response to previous
treatment for their amyloidosis (e.g., chemotherapy, autologous stem cell transplant [ASCT])
and have persistent cardiac dysfunction.
Official Title
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction
Stanford Investigator(s)
Michaela Liedtke
Associate Professor of Medicine (Hematology)
Eligibility
Inclusion Criteria:
1. Age ≥18 years
2. Confirmed diagnosis of systemic AL amyloidosis
3. ≥1 prior systemic plasma cell dyscrasia therapy with at least a partial hematologic
response
4. Cardiac involvement
5. NT-proBNP ≥650
Exclusion Criteria:
1. Non-AL amyloidosis
2. Meets the International Myeloma Working Group (IMWG) definition of Multiple Myeloma
3. NT-proBNP >5000
4. Received Plasma cell directed chemotherapy within 6 months
5. Received autologous stem cell transplant (ASCT) within 12 months
Intervention(s):
drug: NEOD001
drug: Placebo
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061